CDT Equity (NASDAQ:CDT) Shares Down 5.3% – Here’s Why

Shares of CDT Equity Inc. (NASDAQ:CDT) were down 5.3% during trading on Tuesday . The stock traded as low as $0.81 and last traded at $0.8475. Approximately 468,261 shares were traded during trading, a decline of 82% from the average daily volume of 2,621,073 shares. The stock had previously closed at $0.8950.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CDT Equity in a report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

CDT Equity Stock Performance

The stock has a market capitalization of $4.12 million, a price-to-earnings ratio of 0.00 and a beta of 1.44. The firm’s fifty day simple moving average is $3.85 and its 200 day simple moving average is $22.74.

CDT Equity Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.